A federal appeals court strips Prozac of patent protection two years early

On Aug. 9, 2000, a federal appeals court invalidated patent protection for Eli Lilly's blockbuster antidepressant Prozac, a surprise ruling that knocked the company's shares down $31 in a matter of hours ^[1]. The day before, Lilly stock had hit an all-time high of $108 ^[1].

That single day became a reference point inside the company. The Indianapolis Business Journal reported that the date is "seared in the memories of longtime Eli Lilly and Co. executives" ^[1]. The ruling was one of several setbacks that pushed the stock into a long decline, with shares bottoming out at $29 during the depths of the financial crisis in 2008 ^[1].

A decade of patent cliffs

The Prozac loss was only the opening act. By 2010, as then-new CEO John Lechleiter looked ahead through 2014, four more blockbusters were set to lose patent protection: the cancer drug Gemzar, the schizophrenia treatment Zyprexa, the antidepressant Cymbalta and the osteoporosis medicine Evista ^[1]. Together those four had produced $10.4 billion of Lilly's $21.8 billion in 2009 sales — close to half the company's revenue ^[1].

When a patent expires, generic manufacturers can enter and prices typically fall, which is good for patients paying for that drug and bad for the company that sold it. Outside analysts at the time doubted Lilly could survive the hit alone. "They have to do something, or the patent cliff will kill them," Standard & Poor's analyst Herman Saftlas told Reuters in 2010 ^[1].

Lilly's revenue did drop. Total sales peaked at $23.3 billion in 2011 and fell to a seven-year low of $19.6 billion in 2014 ^[1]. By early 2015, J.P. Morgan was forecasting sales would inch back up and reach $25.6 billion in 2020 ^[1]. The company cut costs, kept its 49-cents-per-quarter dividend, and stayed independent rather than merging ^[1]. Lilly shares climbed 45% from October 2013 to above $70 by early 2015, a range they had not traded in for 11 years ^[1].

The lesson Lechleiter drew was explicitly about avoiding a repeat. "We've paid particular attention to putting the company in a position where we do not have to go through the boom and bust cycle that's characterized the last 10 years," he told analysts ^[1].

Why it matters for patients

Patent dates are one of the biggest hidden drivers of what a prescription costs. The Prozac ruling shows the timing can move unexpectedly: a court can end exclusivity earlier than a manufacturer planned, and generics follow. It also shows the other side — companies that face a cliff respond by cutting costs, pricing aggressively on newer products, and pushing hard to launch replacements before the old drugs go generic ^[1].

That history is relevant background for anyone weighing a long-term commitment to a brand-name medicine, including GLP-1 drugs, because the price you pay years from now may depend on litigation and patent expirations that have not been decided yet.

Important caveats: the source used here is a 2015 retrospective about Lilly's recovery under Lechleiter ^[1]. It does not discuss tirzepatide (Mounjaro and Zepbound), orforglipron (Foundayo), or any current GLP-1 patent dates, and it does not address today's list prices or insurance coverage. Those specifics are not known from this reporting.

What happens next

Nothing in this source points to a pending decision. The dated milestones it establishes are historical: the Aug. 9, 2000 ruling; the $29 stock low in 2008; the 2011–2014 revenue decline from $23.3 billion to $19.6 billion; and a 2020 sales forecast of $25.6 billion made in early 2015 ^[1]. Any patent challenges involving current obesity and diabetes drugs would need separate reporting.